• 1
    Nelson DR. The Immunopathogenesis of hepatitis C virus infection. In: Raymond Koff, ed. Clin Liver Dis 2001; 5: 931–953.
  • 2
    Napoli J, Bishop A, McGuinness P, Painter DM, McCaughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996; 24: 759765.
  • 3
    Nelson DR, Lauwers GY, Lau JYN, Davis GL. Interleukin-10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial in interferon nonresponders. Gastroenterology 2000; 118: 655660.
  • 4
    Lau JYN, Davis GL, Brunson ME, Qian KP, Lin HJ, Quan S, DiNello R, et al. Hepatitis C virus infection in renal transplant recipients. Hepatology 1993; 18: 10271031.
  • 5
    Cerny A, McHutchison JG, Pasquinelli C., Brown ME, Brothers MA, Grabscheid B, Fowler P, et al. CTL response to HCV-derived peptides containing the HLA-A2.1 binding motif. J Clin Invest 1995; 95: 521530.
  • 6
    Chang K, Thimme R, Melpolder J, Oldach D, Pemberton J, Moorhead-Loudis J, McHutchison JG, et al. Differential CD4+ and CD8+ T-cell responsiveness in hepatitis C virus infection. Hepatology 2001; 33: 267276.
  • 7
    Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, et al. Cellular immune responses persist, humoral responses decrease two decades after recovery from a single source outbreak of hepatitis C. Nat Med 2000; 6: 578582.
  • 8
    Altman JD, Moss PAH, Goulder PJR, Baroch DH, McHeyzer-Williams, Bell JI, McMichael AJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 9496.
  • 9
    Zhu H, Zhao H, Collins CD, Eckenrode SE, Run Q, McIndoe RA, Crawford JM, et al. Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology 2003; 37: 11801188.
  • 10
    Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2001; 75: 85168523.
  • 11
    Deckert M, Soltek S, Geginat G, Lutjen S, Montesinos-Rongen, Hof H, Schluter D. Endogenous interleukin-10 is required for prevention of a hyperinflammatory intracer immune response in Listeria monocytogenes meningoencephalitis. Infect Immun 2001; 69: 45614571.
  • 12
    Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001; 166: 11411147.
  • 13
    Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, et al. Analysis of a successful immune response against hepatitis C. Immunity 1999; 10: 439449.
  • 14
    Hoffman RM, Diepolder HM, Zachoval R, Zwiebel FM, Jung MC., Scholz S, Nitschko H, et al. Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology 1995; 21: 632638.
  • 15
    Gruner NH, Gerlach TJ, Jung MC., Diepolder HM, Schirren CA, Schraut WW, Hoffmann R, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000; 181: 15281536.
  • 16
    Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC., Eichenlaub D, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C infection. Lancet 1995; 346: 10061007.
  • 17
    Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997; 25: 449457.
  • 18
    Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumav NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346355.
  • 19
    Lohr HF, Schmitz D, Arenz M, Weyer S, Gerken G, Meyer zum Buschenfelde KH. The viral clearance in interferon-treated chronic hepatitis c is associated with increased cytotoxic T cell frequencies. J Hepatol 1999; 31: 407415.
  • 20
    Nelson DR, Marousis CG, Davis GL, Lau JYN. Intrahepatic HCV-specific CTL activity and response to interferon therapy in chronic HCV. Hepatology 1998; 28: 225230.
  • 21
    Lasarte JJ, Garcia-Granero M, Lopez A, Casares N, Garcia N, Civeira MP, Borras-Cuesta F, et al. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology 1998; 28: 815822.
  • 22
    Piazzolla G, Tortorella C., Schiraldi O, Antonaci S. Relationship between interferon-gamma, interleukin-10, and interleukin-12 production in chronic hepatits C and in-vitro effects of interferon-alpha. J Clin Immunol 2000; 20: 5461.
  • 23
    Eskdale J, Keijsers V, Huizinga T, Gallagher G. Microsatellite alleles and single nucleotide polymorphisms combine to form four major haplotype families at the human interleukin-10 locus. Gene Immun 1999; 1: 151155.
  • 24
    Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C., Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999; 30: 526530.
  • 25
    Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346355.
  • 26
    Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683765.
  • 27
    Trinchieri G. Regulatory role of T cells producing both interferon gamma and interleukin 10 in persistent infection. J Exp Med 2001; 194: F53F57.
  • 28
    Lisinski TJ, Furie MB. Interleukin-10 inhibits proinflammatory activation of endothelium in response to Borrelia burgdorferi or lipopolysaccharide but not interleukin-1 beta or tumor necrosis factor alpha. J Leukoc Biol 2002; 72: 503511.
  • 29
    Wedemeyer H, Xiao-Song H, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, Liang TJ, et al. Impaired effector function of hepatitis C virus-specific CD8+ t cells in chronic hepatitis C virus infection. J Immunol 2002; 169: 34473458.
  • 30
    Sakaguchi S. Regulatory T cells: key controllers of immulogic self-tolerance. Cell 2000; 101: 455458.
  • 31
    Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001; 167: 11371140.
  • 32
    Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG. A CD4+ T-cell subset inhibits antigen-specific T cell responses and prevents colitis. Nature 1997; 389: 737742.
  • 33
    Bacchetta R, Sartirana C., Levings MK, Bordignon C., Narula S, Roncarolo MG. Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol 2002; 32: 22372245.
  • 34
    Yang AS, Lattime EC. Tumor-induced interleukin 10 suppresses the ability of splenic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 2003; 63: 21502157.